Usual Care Intervention Research Evaluating the Impact of a Personalized Pharmaceutical Plan on the Duration of Opioid Treatment in Non-cancerous Pain

Not Applicable

• Conditions: Opioid Use; Non-cancerous Pain
• Interventions: Behavioral: Admission conciliation interview; Behavioral: Discharge conciliation interview; Behavioral: Targeted pharmaceutical interview

• Registration Number: NCT05196386
• Lead Sponsor: University Hospital, Rouen

Brief Summary

Many treatments with WHO grade III opioids are being introduced in the rheumatology department for non-cancerous pain. The duration of this treatment prescribed at discharge is often uncontrolled and sometimes leads to significant addiction.

The team at the local pain center recommends an average duration of 28 days for this type of pain. There is a full-time pharmacy intern in the rheumatology department.

The aim of this work is to evaluate the impact of a targeted pharmaceutical interview on the duration of the morphine treatment initiated during hospitalization.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2020-02-04
• Study Start: 2020-08-06
• Status Verified: 2022-01
• Study First Submitted QC: 2022-01-17
• Last Update Submitted: 2022-01-17
• Study First Posted: 2022-01-19
• Last Update Posted: 2022-01-19
• Primary Completion: 2023-03
• Study Completion: 2023-03

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

• Age ≥ 18 and < 75 years old when entering the rheumatology department
• Hospitalization in the rheumatology department
• Patient with acute non-traumatic musculoskeletal disease
• Patient not taking grade III opioid treatment
• Patient affiliated to a social security scheme
• Patient having read and understood the information letter and signed the consent form
• Patient present on a day which the pharmacy intern is present

Exclusion Criteria

• Presence of cancer, fibromyalgia, already diagnosed at inclusion
• Patient does not understand French
• Patient with Current or past opioid addiction
• Person deprived of liberty by administrative or judicial decision

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Patient with targeted pharmaceutical interview	Admission conciliation interview	Specific information about treatment delivered by pharmacist
Patient with targeted pharmaceutical interview	Targeted pharmaceutical interview	Specific information about treatment delivered by pharmacist
Patient without targeted pharmaceutical interview	Discharge conciliation interview	No Specific information about treatment delivered by pharmacist
Patient with targeted pharmaceutical interview	Discharge conciliation interview	Specific information about treatment delivered by pharmacist
Patient without targeted pharmaceutical interview	Admission conciliation interview	No Specific information about treatment delivered by pharmacist

Primary Outcome Measures

Name	Time	Method
Total duration of opioid treatment	6 months

Secondary Outcome Measures

Name	Time	Method
Rate of patients exceeding 28 days of cumulative duration of treatment	6 months
Rate of patients exceeding 90 days of cumulative duration of treatment	6 months

Trial Locations

Locations (1)

Rouen University Hospital; 🇫🇷 Rouen, France